Gene clues could personalize myeloma treatment
NCT ID NCT07514052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether certain gene activity patterns can predict how well the drug selinexor works in people with multiple myeloma that has come back or stopped responding to treatment. Researchers will give 127 participants a weekly selinexor combination and track their response using bone marrow tests and blood work. The goal is to move toward more personalized treatment for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selinexor (a drug taken orally once a week, combined with other standard drugs)
- What this could lead to
- If successful, this could help doctors personalize treatment for multiple myeloma by using gene tests to predict who will benefit most from selinexor-based therapy.
- What could go wrong
- This is an early-stage study focused on finding predictive biomarkers, not proving a cure. The sample size is modest, and the results may not apply to all patients. Selinexor can cause side effects like nausea and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA OF BONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ShanxiBethuneH
RECRUITINGTaiyuan, Shanxi, 030000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.